Infectious complications in patients with lung cancer

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 1, 2013, Pages 8-18

  Akinosoglou, K S ^a   Karkoulias, K ^a   Marangos, M ^a  

^a UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

Author keywords

Infections in oncologic patients; Lung cancer; Pneumonia

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; BETA LACTAM; CARBAPENEM; CEPHALOSPORIN; CLINDAMYCIN; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; MACROLIDE; VORICONAZOLE;

ANTIBIOTIC THERAPY; ARTICLE; ASPIRATION PNEUMONIA; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEBRILE NEUTROPENIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFECTIOUS COMPLICATION; LUNG ABSCESS; LUNG CANCER; LUNG EMBOLISM; LUNG INFECTION; MONOTHERAPY; OPPORTUNISTIC INFECTION; PATHOGENESIS; PNEUMONIA; POSTOPERATIVE INFECTION; SUPERINFECTION; TREATMENT DURATION;

FEVER; HUMANS; LUNG NEOPLASMS; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PNEUMONIA; RESPIRATORY TRACT INFECTIONS;

EID: 84878561994     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (104)

1. PERLIN E, BANG K, SHAH A, HURSEY P, WHITTINGHAM W, HASHMI K, CAMPBELL L, KASSIM O. The impact of pulmonary infections on the survival of lung cancer patients. Cancer 1990; 66: 593-596.
2. KOHNO S, KOGA H, OKA M, KADOTA J, KAKU M, SODA H, TOMONO K, HARA K. The pattern of respiratory infection in patients with lung cancer. Tohoku J Exp Med 1994; 173: 405-411.
3. REMISZEWSKI P, SLODKOWSKA J, WIATR E, ZYCH J, RADOMSKI P, ROWINSKA-ZAKRZEWSKA E. Fatal infection in patients treated for small cell lung cancer in the Institute of Tuberculosis and Chest Diseases in the years 1980-1994. Lung Cancer 2001; 31: 101-110.
4. ROSOLEM M, RABELLO L, LISBOA T, CARUSO P, COSTA T, LEAL V, SALLUH I, SOARES M. Critically ill patients with cancer and sepsis: Clinical course and prognostic factors. J Crit Care 2011. [Epub ahead of print]
5. WATANABE A, NAKAI Y, SAITO J, HONDA Y, TOKUE Y, SUGAWARA S, NUMATA Y, KIKUCHI T, SATO J, MATSUBARA N. Clinical significance of respiratory infections associated with lung cancer patients. Nihon Kyobu Shikkan Gakkai Zasshi 1992; 30: 1250-1256.
6. PUTINATI S, TREVISANI L, GUALANDI M, GUERRA G, ROSSI R, SARTORI S, POTENA A. Pulmonary infections in lung cancer patients at diagnosis. Lung Cancer 1994, 11: 243-249.
7. RANCIC M, RISTIC L, STANKOVIC I. Infective complications in patients with lung cancer. Med Pregl 2010; 63: 643-647.
8. KLASTERSKY J. The infectious complications of bronchial cancer. Rev Mal Respir 1998; 15: 451-459.
9. BERGHMANS T, SCULIER P, KLASTERSKY J. A prospective study of infections in lung cancer patients admitted to the hospital. Chest 2003; 124: 114-20.
10. SARIHAN S, ERCAN I, SARAN A, CETINTAS K, AKALIN H, ENGIN K. Evaluation of infections in non-small cell lung cancer patients treated with radiotherapy. Cancer Detect Prev 2005; 29: 181-188.
11. FUKS Z, PATEL H, HORNEDO J, VAN ECHO A, MOODY M, AISNER J. Infections in patients with non-smallcell lung cancer treated with intensive induction chemotherapy. Med Pediatr Oncol 1986; 14: 255-261.
12. MCDONALD F, ATKINS C. Defective cytostatic activity of pulmonary alveolar macrophages in primary lung cancer. Chest 1990; 98: 881-885.
13. BODEY P. Infection in cancer patients. A continuing association. Am J Med 1986; 81: 11-26.
14. PIZZO PA, MEYERS J, FREIFELD A. Infections in the cancer patient. In Cancer, principles and practice of oncology, De Vita VT; Hellman S; Rosenberg SA, Eds. JB Lippincott Company: Philadelphia, 1993; pp. 2292-2337.
15. MANDELL A, WUNDERINK G, ANZUETO A, BARTLETT G, CAMPBELL D, DEAN C, DOWELL F, FILE M, MUSHER M, NIEDERMAN S, TORRES A, WHITNEY G. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: 27-72.
16. RELLO J, BODI M, MARISCAL D, NAVARRO M, DIAZ E, GALLEGO M, VALLES J. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 2003; 123: 174-180.
17. KOURBETI S, MASLOW J. Nontuberculous mycobacterial infections of the lung. Curr Infect Dis Rep 2000; 2: 193-200.
18. BORDIGNON V, BULTRINI S, PRIGNANO G, SPERDUTI I, PIPERNO G, BONIFATI C, FILIPPETTI M, TOMA L, LATINI A, DI CECIO M, GIULIANI A, VOCATURO A, TRENTO A, FRANCESCONI F, CATALDO A, VENTO A, CILENTI V, BERARDESCA E, AMEGLIO F, CORDIALI FEI P, ENSOLI F. High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer. J Biol Regul Homeost Agents 2011; 25: 213-220.
19. LIM S, BAUDOUIN V, GEORGE C, HILL T, JAMIESON C, LE JEUNE I, MACFARLANE T, READ C, ROBERTS J, LEVY L, WANI M, WOODHEAD A. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64: 1-55.
20. THORNSBERRY C, SAHM F. Antimicrobial resistance in respiratory tract pathogens: results of an international surveillance study. Chemotherapy 2000; 46: 15-23.
21. FILE M. Appropriate use of antimicrobials for drugresistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 34: 17-26.
22. WHITNEY G, FARLEY M, HADLER J, HARRISON H, LEXAU C, REINGOLD A, LEFKOWITZ L, CIESLAK R, CETRON M, ZELL R, JORGENSEN H, SCHUCHAT A. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917-1924.
23. HEFFELFINGER D, DOWELL F, JORGENSEN H, KLUGMAN P, MABRY R, MUSHER M, PLOUFFE F, RAKOWSKY A, SCHUCHAT A, WHITNEY G. Management of community- acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 1399-1408.
24. BANDAK I, TURNAK R, ALLEN S, BOLZON D, PRESTON A, BOUCHILLON K, HOBAN J. Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries. Eur J Clin Microbiol Infect Dis 2001; 20: 55-60.
25. MIYAMOTO J, KOGA H, KOHNO S, TAIRA K, TOMONO K, KAKU M, HARA K. Clinical investigation of obstructive pneumonia with lung cancer. Kansenshogaku Zasshi 1994; 68: 728-733.
26. HILL K, SANDERS V. Anaerobic disease of the lung. Infect Dis Clin North Am 1991; 5: 453-466.
27. MARIK E. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001, 344: 665-671.
28. MARIK E, CAREAU P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. Chest 1999, 115: 178-183.
29. TSENG L, WU H, LIN Y, LAI W, LIU C. Surgery for lung abscess in immunocompetent and immunocompromised children. J Pediatr Surg 2001; 36 : 470-473.
30. LIAW S, YANG C, WU G, YU J, CHANG B, LEE N, KUO H, LUH T. The bacteriology of obstructive pneumonitis. A prospective study using ultrasoundguided transthoracic needle aspiration. Am J Respir Crit Care Med 1994; 149: 1648-1653.
31. HOFFER A, BLOOM A, COLIN A, FISHMAN J. Lung abscess versus necrotizing pneumonia: implications for interventional therapy. Pediatr Radiol 1999; 29: 87-91.
32. ROLSTON V. The spectrum of pulmonary infections in cancer patients. Curr Opin Oncol 2001; 13: 218-223.
33. FILAIRE M, MOM T, LAURENT S, HAROUNA Y, NAAMEE A, VALLET L, NORMAND B, ESCANDE G. Vocal cord dysfunction after left lung resection for cancer. Eur J Cardiothorac Surg 2001; 20: 705-711.
34. SHAHID M, MALIK A, BHARGAVA R. Bronchogenic carcinoma and secondary aspergillosis-common yet unexplored: evaluation of the role of bronchoalveolar lavage-polymerase chain reaction and some nonvalidated serologic methods to establish early diagnosis. Cancer 2008; 113: 547-558.
35. HERBRECHT R, DENNING W, PATTERSON F, BENNETT E, GREENE E, OESTMANN W, KERN V, MARR A, RIBAUD P, LORTHOLARY O, SYLVESTER R, RUBIN H, WINGARD R, STARK P, DURAND C, CAILLOT D, THIEL E, CHANDRASEKAR H, HODGES R, SCHLAMM T, TROKE F, DE PAUW B. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
36. GROLL H, WALSH J. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001; 10: 1545-1558.
37. WILKIN A, FEINBERG J. Pneumocystis carinii pneumonia: a clinical review. Am Fam Physician 1999; 60: 1699-1708, 1713-1714.
38. SHELHAMER H, TOEWS B, MASUR H, SUFFREDINI F, PIZZO A, WALSH J, HENDERSON K. NIH conference. Respiratory disease in the immunosuppressed patient. Ann Intern Med 1992; 117: 415-431.
39. NAN N, FERNANDEZ-AYALA M, FARINAS-ALVAREZ C, MONS R, ORTEGA J, GONZALEZ-MACIAS J, FARINAS C. Nosocomial infection after lung surgery: incidence and risk factors. Chest 2005; 128: 2647-2652.
40. BUSCH E, VERAZIN G, ANTKOWIAK G, DRISCOLL D, TAKITA H. Pulmonary complications in patients undergoing thoracotomy for lung carcinoma. Chest 1994; 105: 760-766.
41. DESLAURIERS J, GINSBERG J, PINTADOSI S, FOURNIER B. Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer. Chest 1994; 106: 329-330.
42. PATEL L, TOWNSEND R, FOUNTAIN W. Elective pneumonectomy: factors associated with morbidity and operative mortality. Ann Thorac Surg 1992; 54: 84-88.
43. STEPHAN F, BOUCHESEICHE S, HOLLANDE J, FLAHAULT A, CHEFFI A, BAZELLY B, BONNET F. Pulmonary complications following lung resection: a comprehensive analysis of incidence and possible risk factors. Chest 2000; 118: 1263-1270.
44. DUQUE L, RAMOS G, CASTRODEZA J, CEREZAL J, CASTANEDO M, YUSTE G, HERAS F. Early complications in surgical treatment of lung cancer: a prospective, multicenter study. Grupo Cooperativo de Carcinoma Broncogenico de la Sociedad Espanola de Neumologia y Cirugia Toracica. Ann Thorac Surg 1997; 63: 944-950.
45. SCHUSSLER O, ALIFANO M, DERMINE H, STRANO S, CASETTA A, SEPULVEDA S, CHAFIK, A, COIGNARD S, RABBAT A, REGNARD F. Postoperative pneumonia after major lung resection. Am J Respir Crit Care Med 2006; 173: 1161-1169.
46. IOANAS M, ANGRILL J, BALDO X, ARANCIBIA F, GONZALEZ J, BAUER T, CANALIS E, TORRES A. Bronchial bacterial colonization in patients with resectable lung carcinoma. Eur Respir J 2002; 19: 326-332.
47. BELDA J, CAVALCANTI M, FERRER M, SERRA M, PUIG DE LA BELLACASA J, CANALIS E, TORRES A. Bronchial colonization and postoperative respiratory infections in patients undergoing lung cancer surgery. Chest 2005; 128: 1571-1579.
48. SOK M, DRAGAS Z, ERZEN J, JERMAN J. Sources of pathogens causing pleuropulmonary infections after lung cancer resection. Eur J Cardiothorac Surg 2002; 22: 23-27.
49. HOFFKEN G, NIEDERMAN S. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002; 122: 2183-2196.
50. NAGASAKI F, FLEHINGER J, MARTINI N. Complications of surgery in the treatment of carcinoma of the lung. Chest 1982; 82: 25-29.
51. MITAS L, HORVATH T, SOBOTKA M, GARAJOVA B, HANKE I, KALA Z, PENKA I, IVICIC J, VOMELA J. Complications in patients undergoing pulmonary oncological surgery. Rozhl Chir 2010; 89: 113-117.
52. RADU M, JAUREGUY F, SEGUIN A, FOULON C, DESTABLE D, AZORIN J, MARTINOD E. Postoperative pneumonia after major pulmonary resections: an unsolved problem in thoracic surgery. Ann Thorac Surg 2007; 84: 1669-1673.
53. KHAN A, WINGARD R. Infection and mucosal injury in cancer treatment. J Natl Cancer Inst Monogr 2001; 29: 31-36.
54. JONES A, AVRITSCHER B, COOKSLEY D, MICHELET M, BEKELE N, ELTING S. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 2006; 14: 505-515.
55. NIRENBERG A, BUSH P, DAVIS A, FRIESE R, GILLESPIE W, RICE D. Neutropenia: state of the knowledge part I. Oncol Nurs Forum 2006; 33: 1193-1201.
56. CHOI W, MUNDEN F, ERASMUS J, PARK J, CHUNG K, JEON C, PARK K. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics 2004; 24: 985-997.
57. WERNER-WASIK M, YU X, MARKS B, SCHULTHEISS E. Normal- tissue toxicities of thoracic radiation therapy: esophagus, lung, and spinal cord as organs at risk. Hematol Oncol Clin North Am 2004; 18: 131-160.
58. VAZQUEZ A, SOBEL D. Mucosal candidiasis. Infect Dis Clin North Am 2002; 16: 793-820.
59. SARAL R. Oral complications of cancer therapies. Management of acute viral infections. NCI Monogr 1990; 9: 107-110.
60. VILLANUEVA A, GOTUZZO E, ARATHOON G, NORIEGA M, KARTSONIS A, LUPINACCI J, SMIETANA M, DINUBILE J, SABLE A. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-299.
61. HUGHES T, ARMSTRONG D, BODEY P, BOW J, BROWN E, CALANDRA T, FELD R, PIZZO A, ROLSTON V, SHENEP L, YOUNG S. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
62. BODEY P, BUCKLEY M, SATHE S, FREIREICH J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
63. FUJITA M, TOKUNAGA S, IKEGAME S, HARADA E, MATSUMOTO T, UCHINO J, WATANABE K, NAKANISHI Y. Identifying risk factors for refractory febrile neutropenia in patients with lung cancer. J Infect Chemother 2012; 18: 53-58.
64. NOVAKOVA R, DONNELLY P, DE PAUW B. Potential sites of infection that develop in febrile neutropenic patients. Leuk Lymphoma 1993; 10: 461-467.
65. RIKIMARU T, ICHIKI M, OOKUBO Y, MATUMOTO K, MIMORI Y, SUEYASU Y, KINOSHITA M, YANO H, SHIRAISHI T, OIZUMI K. Prognostic significance of febrile episodes in lung cancer patients receiving chemotherapy. Support Care Cancer 1998; 6: 396-401.
66. WISPLINGHOFF H, SEIFERT H, WENZEL P, EDMOND B. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103-1110.
67. BOCHUD Y, CALANDRA T, FRANCIOLI P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994; 97: 256-264.
68. LANOIX P, PLUQUET E, LESCURE X, BENTAYEB H, LECUYER E, BOUTEMY M, DUMONT P, JOUNIEAUX V, SCHMIT L, DAYEN C, DOUADI Y. Bacterial infection profiles in lung cancer patients with febrile neutropenia. BMC Infect Dis 2011; 11: 183.
69. MARKMAN M, ABELOFF D. Management of hematologic and infectious complications of intensive induction therapy for small cell carcinoma of the lung. Am J Med 1983; 74: 741-746.
70. NIHO S, OHE Y, GOTO K, OHMATSU H, MATSUMOTO T, KUBOTA K, KAKINUMA R, NISHIWAKI Y. Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer. Jpn J Clin Oncol 2004; 34: 69-73.
71. MATSUI K, MASUDA N, TAKADA M, KUSUNOKI Y, FUKUOKA M. A randomized trial comparing imipenem/ cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer. Jpn J Clin Oncol 1991; 21: 428-434.
72. CORDONNIER C, BUZYN A, LEVERGER G, HERBRECHT R, HUNAULT M, LECLERCQ R, BASTUJI-GARIN S. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003; 36: 149-158.
73. FURNO P, BUCANEVE G, DEL FAVERO A. Monotherapy or aminoglycoside- containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2: 231-242.
74. TALCOTT A, FINBERG R, MAYER J, GOLDMAN L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988; 148: 2561-2568.
75. KLASTERSKY J, PAESMANS M, RUBENSTEIN B, BOYER M, ELTING L, FELD R, GALLAGHER J, HERRSTEDT J, RAPOPORT B, ROLSTON K, TALCOTT J. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying lowrisk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051.
76. TALCOTT A, SIEGEL D, FINBERG R, GOLDMAN L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10: 316-322.
77. KLASTERSKY J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004; 39: 32-37.
78. BODEY P. Unusual presentations of infection in neutropenic patients. Int J Antimicrob Agents 2000; 16: 93-95.
79. CRAWFORD W. Noninfectious lung disease in the immunocompromised host. Respiration 1999; 66: 385-395.
80. VENTO S, CAINELLI F, TEMESGEN Z. Lung infections after cancer chemotherapy. Lancet Oncol 2008; 9: 982-992.
81. KLASTERSKY J, AOUN M. Opportunistic infections in patients with cancer. Ann Oncol 2004; 15: 29-35.
82. HEUSSEL P, KAUCZOR U, HEUSSEL G, FISCHER B, MILDENBERGER P, THELEN M. Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT. AJR Am J Roentgenol 1997; 169: 1347-1353.
83. BROWN J, MILLER R, MULLER L. Acute lung disease in the immunocompromised host: CT and pathologic examination findings. Radiology 1994; 190: 247-254.
84. BOERSMA G, ERJAVEC Z, VAN DER WERF S, DE VRIESHOSPER G, GOUW S, MANSON L. Bronchoscopic diagnosis of pulmonary infiltrates in granulocytopenic patients with hematologic malignancies: BAL versus PSB and PBAL. Respir Med 2007; 101: 317-325.
85. VALDIVIESO M, GIL-EXTREMERA B, ZORNOZA J, RODRIQUEZ V, BODEY P. Gram-negative bacillary pneumonia in the compromised host. Medicine (Baltimore) 1977; 56: 241-254.
86. JAIN P, SANDUR S, MELI Y, ARROLIGA C, STOLLER K, MEHTA C. Role of flexible bronchoscopy in immunocompromised patients with lung infiltrates. Chest 2004; 125: 712-722.
87. MURRAY V, O'BRIEN E, PADHANI R, POWLES R, CUNNINGHAM D, JEANES A, ASHLEY S. Use of first line bronchoalveolar lavage in the immunosuppressed oncology patient. Bone Marrow Transplant 2001; 27: 967-971.
88. LIAO Y, LIAW S, WANG C, CHEN Y, LUH T, YANG C. Bacteriology of infected cavitating lung tumor. Am J Respir Crit Care Med 2000; 161: 1750-1753.
89. BATES H, CAMPBELL D, BARRON L, MCCRACKEN A, MORGAN N, MOSES B, DAVIS M. Microbial etiology of acute pneumonia in hospitalized patients. Chest 1992; 101: 1005-1012.
90. ELLIS E, SPENCE D, BOUCHAMA A, ANTONIUS J, BAZARBASHI M, KHOUGEER F, DE VOL B. Open lung biopsy provides a higher and more specific diagnostic yield compared to broncho-alveolar lavage in immunocompromised patients. Fungal Study Group. Scand J Infect Dis 1995; 27: 157-162.
91. RANO A, AGUSTI C, BENITO N, ROVIRA M, ANGRILL J, PUMAROLA T, TORRES A. Prognostic factors of non- HIV immunocompromised patients with pulmonary infiltrates. Chest 2002; 122: 253-261.
92. SHAHID M, MALIK A, BHARGAVA R. Increasing secondary bacterial infections with Enterobacteriaceae harboring bla (CTX-M-15) and bla(CMY-6) in patients with bronchogenic carcinoma: an emerging point of concern. Asian Pac J Trop Med 2011; 4: 5-12.
93. TJAN-HEIJNEN C, POSTMUS E, ARDIZZONI A, MANEGOLD H, BURGHOUTS J, VAN MEERBEECK J, GANS S, MOLLERS M, BUCHHOLZ E, BIESMA B, LEGRAND C, DEBRUYNE C, GIACCONE G. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebocontrolled phase III study. Ann Oncol 2001; 12: 1359-1368.
94. CUL LEN M, STEVEN N, BILLINGHAM L, GAUNT C, HASTINGS M, SIMMONDS P, STUART N, REA D, BOWER M, FERNANDO I, HUDDART R, GOLLINS S, STANLEY A. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353: 988-998.
95. GAFTER-GVILI A, FRASER A, PAUL M, LEIBOVICI L. Metaanalysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-995.
96. CRAWFORD J, OZER H, STOLLER R, JOHNSON D, LYMAN G, TABBARA I, KRIS M, GROUS J, PICOZZI V, RAUSCH G ET AL. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-170.
97. KUDERER M, DALE C, CRAWFORD J, LYMAN H. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25: 3158-3167.
98. DRINGS P, FISCHER R. Biology and clinical use of GM-CSF in lung cancer. Lung 1990; 168: 1059-1068.
99. SMITH J, KHATCHERESSIAN J, LYMAN H, OZER H, ARMITAGE O, BALDUCCI L, BENNETT L, CANTOR B, CRAWFORD J, CROSS J, DEMETRI G, DESCH E, PIZZO A, SCHIFFER A, SCHWARTZBERG L, SOMERFIELD R, SOMLO G, WADE C, WADE L, WINN J, WOZNIAK J, WOLFF C. 2006 update of recommendations for the use of white blood cell growth factors: an evidencebased clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
100. ETTINGER S, COX D, GINSBERG J, KOMAKI R, KRIS G, LIVINGSTON B, SUGARBAKER J. NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 1996; 10: 81-111.
101. BERGHMANS T, PAESMANS M, LAFITTE J, MASCAUX C, MEERT P, SCULIER P. Role of granulocyte and granulocyte- macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 2002; 37: 115-123.
102. GROSSI F, TISEO M. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol 2006; 58: 221-230.
103. MEROPOL J, MILLER L, KORN L, BRAITMAN E, MACDERMOTT L, SCHUCHTER M. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992; 84: 1201-1203.
104. BUNN JR, CROWLEY J, KELLY K, HAZUKA B, BEASLEY K, UPCHURCH C, LIVINGSTON R, WEISS R, HICKS J, GANDARA R et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13: 1632-1641.